December 19, 2024 7:00 AM EST
Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results
December 17, 2024 4:05 PM EST
Regeneron Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
December 17, 2024 7:00 AM EST
EYLEA HD® (aflibercept) Injection 8 mg Phase 3 Trial Meets Primary Endpoint Showing Improved Vision with Extended Dosing Intervals in Patients with Macular Edema following Retinal Vein Occlusion
December 16, 2024 4:30 PM EST
Regeneron Named to Dow Jones Sustainability World Index for Sixth Consecutive Year
December 9, 2024 5:45 PM EST
Odronextamab ASH Presentations Underscore Impressive Potential in Earlier Lines of Treatment and Additional Types of Lymphoma
December 7, 2024 7:00 PM EST
Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab
November 15, 2024 12:59 AM EST
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)
November 13, 2024 7:00 AM EST
Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH
November 11, 2024 4:05 PM EST
Regeneron Announces Investor Conference Presentations
November 6, 2024 1:00 AM EST